Global Health Policy

SHERIDAN, WYOMING – July 29, 2025 – The American Medical Association (AMA) has issued a public plea urging Health Secretary Robert F. Kennedy Jr. to preserve the U.S. Preventive Services Task Force (USPSTF), following reports that the panel could be dissolved due to ideological concerns. The potential shakeup, while not yet finalized, has sparked widespread concern across the healthcare community and could significantly impact access to preventive care services nationwide.

SHERIDAN, WYOMING – July 29, 2025 – Sarepta Therapeutics is once again under regulatory spotlight following the death of an 8-year-old boy in Brazil who had received its gene therapy Elevidys, triggering an FDA investigation and fresh market turbulence for the embattled biotech.

SHERIDAN, WYOMING – July 25, 2025 – Royal Philips (NYSE: PHG, AEX: PHIA) has confirmed the exchange ratio for its 2024 dividend, announcing a share-based conversion rate of one new common share for every 23.6353 existing shares. The ratio was determined based on the volume-weighted average price of Philips shares traded on Euronext Amsterdam across May 30, June 2, and June 3, 2025, which stood at EUR 20.0600.

SHERIDAN, WYOMING – July 25, 2025 – In a significant move reshaping national vaccine policy, the U.S. Department of Health and Human Services (HHS) has announced it will eliminate thimerosal from all influenza vaccines distributed in the United States. The decision follows a unanimous vote by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) on June 26, 2025, and marks the end of an era for a preservative that has been both a practical necessity and a source of public debate for over two decades.

SHERIDAN, WYOMING – July 25, 2025 – A recent string of awkward and, at times, insensitive employee layoff notifications in the biopharma industry is sparking serious concerns around internal communications, HR protocol, and employer branding amid rising workforce reductions.

SHERIDAN, WYOMING – July 25, 2025 – Roche has announced a significant step in the modernization of its capital structure, as its Board of Directors proposes to exchange the company's non-voting equity securities ("Genussscheine") for newly issued participation certificates. The proposal, which will be submitted to shareholders for approval at the 2026 Annual General Meeting (AGM), aims to align Roche’s capital instruments with current Swiss corporate law and modern market practices.

SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. (NYSE: GMED), a global leader in musculoskeletal solutions, today announced a significant strategic initiative with the authorization of a share repurchase program of up to $500 million of the company’s outstanding common stock. The move underscores Globus Medical’s confidence in its long-term business fundamentals and commitment to delivering sustained value for shareholders.

Strategic Response to Market Valuation Trends

SHERIDAN, WYOMING – July 21, 2025 – Facing industry-wide uncertainty and hiring slowdowns, biopharma companies are increasingly turning to fractional roles to fill critical talent gaps—an emerging trend reshaping workforce strategies across the sector. Recent insights from recruiters and professionals reveal a growing openness to flexible, project-based roles that offer companies agility while providing experienced professionals with continued engagement in the field.

Fractional Work Gains Traction Amid Market Challenges

SHERIDAN, WYOMING – July 21, 2025 – Bristol Myers Squibb (BMS) and Pfizer have announced a strategic move to offer their blockbuster blood thinner Eliquis directly to U.S. patients at a 40% discount off the current list price—marking a significant shift in their market approach ahead of Medicare’s negotiated pricing, which takes effect in 2026.

SHERIDAN, WYOMING – July 21, 2025 – Novartis is intensifying its strategic push to relocate key drug manufacturing operations to the United States, aiming to safeguard its U.S. market position against potential tariff impacts. In its second-quarter earnings call last Thursday, CEO Vas Narasimhan emphasized the urgency of reshoring production, while acknowledging the complexity of fully transitioning manufacturing operations.

Novartis Targets Full U.S. Production for Key Medicines